Executive vice president of global health sciences and regulatory affairs at the Medicines Company, Loretta Itri handles worldwide and clinical development oversight. In her free time, Loretta Itri is an avid theater-goer and subscribes to such New York-based companies as the Roundabout Theatre Company. As a part of its mission to share stories from some of the finest theatre artists, the Roundabout Theatre Company maintains its New Play Initiative, a project that seeks to bring about new works and highlight gifted playwrights. The Initiative stemmed from the company’s development into a leading Broadway producer of contemporary and classic revivals in 1995. As Roundabout grew in size and popularity, so did its commitment to producing new plays and, eventually, the New Play Initiative was established. Taking a three-step approach to bringing new plays into the spotlight, the New Play Initiative commissions new works, conducts workshops and readings, and produces those new works as mainstage productions and through the Roundabout Underground program. Over the past two decades, the Initiative has produced dozens of new works, along with workshops for more than 170 works, and 36 playwright commissions.
0 Comments
|
AuthorAs chief medical officer and president of pharmaceutical development at a public biotech company, Dr. Loretta Itri oversaw the worldwide development of a number of important drugs, including Tesetaxel, a novel oral taxane used in the treatment of breast, gastric, and prostate cancer. Archives
October 2019
Categories |